

Drug and Therapeutics Committee – Minutes –approved

Date / Time	Thursday 13 th October 2016
Venue	The Board Room, Alderson House, HRI
Chair	Dr O Ogunbambi, Consultant Rheumatologist
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG) and Vanessa Wear, PA to David Corral, Chief Pharmacist
Quorate: Yes / No	Yes

Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Mr P O'Brien, Deputy Chief Pharmacist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr F Umerah, Consultant Anaesthetist Dr H Klonin, Consultant Paediatrician Dr Roper, Chair, Hull CCG Mr K McCorry, Medicines Management, East Riding
-------------------	---

Apologies	Prof A Morice, Chair, Professor of Respiratory Medicine Prof M Lind, Vice Chair, Professor of Oncology Mr R Kapur, Vascular Surgeon
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2016.10.01	Apologies	As above.					
2016.10.02	Declarations of Interest	HK - Lunch provided by the drug company promoting Ayendi Nasal Spray.	Noted	No further action			10/16
2016.10.03	Minutes of the previous meeting	The minutes were accepted as a true record.					10/16
2016.10.04	Action Tracker	<p>Action Tracker DC had met up with the Sue Philips, a potential lay member for SMPC and D&TC. She plans to start attending D&TC from November.</p> <p>New Product Requests - Tedizolid It has been agreed that this can be used as a 2nd line agent for a short course (e.g. 6 days) orally and this is covered within the PbR tariff. Long term use is not within tariff, so has not been approved. This requires further discussion.</p>	<p>Action complete</p> <p>Ongoing</p>		KMcC/ POB	9/16	10/16
	Action Tracker	<p>New Product Requests - Evolocumab and Alirocumab</p> <p>POB informed the committee that he had fed back to YH & DN, as requested. The revised form had been circulated to D&TC members, with drug history added. A circulated report from the last two months showed that there was a significant benefit to patients. The service had also identified several patients who did not meet the NICE criteria or who had not been on optimised oral therapy prior to referral, who would be referred back to their GP. It was requested that a further update would be useful in four to six months, and this should be discussed at MMIG.</p>		Action complete			10/16

	Action Tracker	<p>NICE Guidance – July 16</p> <p>TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa</p> <p>POB has confirmed that NHSE have now identified HEY as a centre for this condition and we will be commissioned to use Adalimumab in HS. A D&T new product request would be sought from the service. POB had contacted Greg Haire and was awaiting a response.</p> <p>TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer</p> <p>TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus</p>	<p>Ongoing</p> <p>Ongoing</p> <p>OO has asked for an application</p>	<p>POB awaiting response from Greg Haire</p> <p>ML to seek application</p> <p>Action complete</p>	<p>POB</p> <p>ML</p>	<p>8/16</p> <p>8/16</p>	<p>10/16</p>
	Action Tracker	<p>New Product requests</p> <ul style="list-style-type: none"> • Lumicaftor-Ivacaftor • Artesunate <p>NHSE Approved HIV preps:</p> <ul style="list-style-type: none"> • Daranavir/Cobicistat (Rezolsta) • Atazanavir/Cobicistat (Evotaz) • Elviregravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) <p>NHSE Approved Hepatitis C preps:</p> <ul style="list-style-type: none"> • NICE TA 364 – Daclatasvir (Daclenza) • NICE TA 365 - Ombitasvir/Paritaprevir/Ritonavir (Viekirax) • NICE TA 363 - Sofosbivir/Ledipasvir (Harvoni) • NICE TA 365 – Dasabuvir (Exviera) 	<p>AM has written to applicants</p> <p>WH has updated formulary</p>	<p>Action complete</p> <p>Action complete</p>			<p>10/16</p> <p>10/16</p>
	Action Tracker	<p>MHRA DSU</p> <p>AM has written to the renal team re Warfarin and Calciphylaxis in end stage renal disease</p>		<p>Action complete</p>			<p>10/16</p>

	Action Tracker	Minutes from HERPC - July 2016 DR had discussed AREDS with the prescribing leads. The position remained the same – ER not commissioning AREDS or AREDS2, Hull only commissioning AREDS, not AREDS2.		Action complete			10/16
2016.10.05	New product requests	<p>Dexmedetomidine (Dexdor) – Dr I Smith Approved. Concerns were raised at the committee regarding side effects. It was suggested that the applicant asks a junior doctor to audit its use for a few months, and feed back to the committee.</p> <p>Diamorphine Nasal Spray (Ayendi) – Dr E Herrievan Approved. Safety and efficacy were demonstrated in the published papers, but there were issues raised regarding the appropriate handling and storage as a controlled drug. The committee agreed this should go to SMPC for further discussion about this.</p> <p>Recombinant Factor IX & VII Blood Clotting Factors agents – Dr D Allsup</p> <ul style="list-style-type: none"> • Elocta® (efmoroctocog alfa, Swedish Orphan Biovitrum) • Nuwiq® (simoctocog alfa, Octapharma) • Rixubis® (nonacog gamma, Baxalta/Shire) • Alprolix® (eftrenonacog alfa, Swedish Orphan Biovitrum) • Idelvion® (albutrepenonacog alfa, CSL Behring) <p>These 5 enhanced half-life coagulation factor concentrates were specialist commissioned by NHSE, in line with the 2 agreements:</p> <ul style="list-style-type: none"> • NHS National Framework Agreement for the supply of Recombinant Factor IX Blood Clotting Factors - Contract Reference Number CM/PHS/14/5434 • NHS National Framework Agreement for the supply of Human Cell Line Recombinant Factor VIII products for the treatment of bleeding disorders - Contract Reference Number CM/PHS/16/5501 	<p>Approved, with audit & feedback</p> <p>Approved, but to be discussed further at SMPC</p> <p>Approved in line with NHSE commissioning and the Department of Health's Commercial Medicines Unit national agreements</p>	<p>OO to write to applicants</p> <p>SG to update formulary</p> <p>DC to agenda Ayendi at SMPC</p> <p>SG to update formulary</p>	<p>OO</p> <p>SG</p> <p>DC</p> <p>SG</p>	<p>11/16</p> <p>11/16</p> <p>11/16</p> <p>11/16</p>	

2016.10.06	NICE Guidance	<p>August 16</p> <ul style="list-style-type: none"> • NG 53 - Transition between inpatient mental health settings and community or care home settings • TA 401 - Bosutinib for previously treated chronic myeloid leukaemia • TA 402 - Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin • TA 403 - Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer • TA 404 - Degarelix for treating advanced hormone-dependent prostate cancer • TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer • TA 391 – Review - Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel • CG156 - Review - Fertility problems: assessment and treatment • CG 141 – Review - Acute upper gastrointestinal bleeding in over 16s: management • CG 142 - Review - Autism spectrum disorder in adults: diagnosis and management 	<p>Not a HEY issue – for HFT</p> <p>On CDF list, not formulary</p> <p>Already on formulary and CDF list</p> <p>Not recommended by NICE</p> <p>On Formulary</p> <p>Not on formulary. Application needed.</p> <p>On CDF list, not formulary</p> <p>No changes</p> <p>No changes</p> <p>No changes</p>	<p>No further action</p> <p>ML to seek application</p> <p>No further Action</p> <p>No Further Action</p> <p>No Further Action</p> <p>ML to seek application</p> <p>ML to seek application</p> <p>No further Action</p> <p>No Further Action</p> <p>No Further Action</p>	<p></p> <p>ML</p> <p></p> <p></p> <p>ML</p> <p>ML</p> <p></p> <p></p> <p></p>	<p></p> <p>11/16</p> <p></p> <p></p> <p>11/16</p> <p>11/16</p> <p></p> <p></p> <p></p>	<p>10/16</p> <p></p> <p>10/16</p> <p>10/16</p> <p>10/16</p> <p></p> <p>10/16</p> <p>10/16</p> <p>10/16</p>
------------	---------------	--	---	--	---	--	--

	<ul style="list-style-type: none"> CG 140 – Review - Palliative care for adults: strong opioids for pain relief CG 126 - Review - Stable angina: management CG 44 – Review - Heavy menstrual bleeding: assessment and management 	No changes	No Further Action			10/16
		No changes	No Further Action			10/16
		Ulipristal added, but already on formulary	No Further Action			10/16
	September 16					
	<ul style="list-style-type: none"> NG 54 - Mental health problems in people with learning disabilities: prevention, assessment and management NG 55 - Harmful sexual behaviour among children and young people NG 56 - Multimorbidity: clinical assessment and management 	Applicable to HFT, not HEY	No Further Action			10/16
		Applicable to HFT, not HEY	No Further Action			10/16
		Includes medicines optimisation, but does not affect formulary	No Further Action			10/16
	<ul style="list-style-type: none"> TA 406 - Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer TA 407 - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors 	On CDF list, not formulary	ML to seek application			11/16
		Already on formulary - for Dermatology only	Amend formulary to add Rheumatology, agenda at MMIG – to review pathway	SG		11/16

		<ul style="list-style-type: none"> • TA 408 - Pegaspargase for treating acute lymphoblastic leukaemia • TA 409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion • TA 410 - Talimogene laherparepvec for treating unresectable metastatic melanoma • TA 411 - Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer • TA 412 - Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases • CG 181 – Review - Cardiovascular disease: risk assessment and reduction, including lipid modification • CG 42 – Review - Dementia: supporting people with dementia and their carers in health and social care 	Not on formulary	ML to seek application	ML	11/16	
			Already on formulary	No Further Action			10/16
			Not on formulary	ML to seek application		11/16	
			Not recommended by NICE, not on formulary	No Further Action			10/16
			Already on formulary	No Further Action			10/16
			High intensity statin treatment defined, does not affect formulary	No Further Action			10/16
			Updated as per NG54, does not affect formulary	No Further Action			10/16
2016.10.07	MHRA Drug Safety Update	<p>August 16 Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias</p> <p>September 16 Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy</p>	Contents noted	No Further Action			10/16
			Usually community use	No Further Action			10/16

		Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable	Dealt with at SMPC	No Further Action			10/16
		Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection	Contents noted	No Further Action			10/16
2016.10.08	Minutes from SMPC July 2016	DC reported that the following items were discussed: <ul style="list-style-type: none"> • Paracetamol IV doses audit & Rotherham coroner's report • Missed doses • Medication Rounds • Homecare • E prescribing on ward C29 (from April 2017) • Addiphos has been approved for use on ITUs, training will be required HK raised the issue of having a dedicated prescribing area on wards, to reduce prescriber interruptions. She would e-mail DC, for the SMPC agenda.	Noted	No Further Action			10/16
2016.10.09	Minutes from the HERPC July 2016	DC reported that the following items were discussed: <ul style="list-style-type: none"> • AREDS/AREDS2 • Dulaglutide – guideline led • Sacubitril-valsartan – PIL to be produced 	Noted	No Further Action			10/16
2016.10.10	Correspondence Received	Ivermectin cream/Rosacea pathway – Dr R Zaman SPG had received a Rosacea flow chart, including use of ivermectin. It still contained errors / was incomplete, so needed further amendment. Anticoagulation for children, shared care with Leeds – tinzaparin & heparin IV infusion chart – Ann Kristensen This chart had been adapted from the one in use in Leeds, to facilitate shared care of children between Leeds & Hull. It had already been reviewed by Dr Allsup and approved at Thrombosis Committee. SPG also discussed that it would be desirable for patients transferred from Leeds on tinzaparin to remain on that agent if under shared care, rather than change drug with associated risks.	To be amended by Dr Zaman Chart approved Tinzaparin to be annotated on formulary for	SPG to liaise with Dr Zaman SG to amend formulary	SPG SG	11/16 11/16	10/16

		<p>The committee agreed to add tinzaparin to the formulary for paediatric use in this way.</p> <p>Stalevo & generic switching - POB POB had correspondence with KMcC regarding the switching of Stalevo to generic versions of this antiparkinsonian agent. There had also been previous discussion at HERPC. It was reported that some patients had switched from Stalevo and their symptoms had been less well controlled on the generic agent. The committee requested that feedback was obtained from Dr Ming, Consultant Neurologist, HEY – to establish what problems had been encountered, for how many patients and with which products.</p> <p>Diclofenac Review – POB POB had produced and circulated a review of Diclofenac usage, based on the Define database, which showed HEY was one of the highest users in the region. Usage was mainly in maternity areas, where it was previously agreed to continue with diclofenac as young women were unlikely to have cardiovascular risk factors and be affected by the MHRA warnings. The circulated Medicines Information review showed that there was little evidence to suggest diclofenac was any better than ibuprofen, and that NICE Guidance CG132 on Caesarean Section recommends ibuprofen. The committee agreed that this should be raised with the F&W health group for further discussion, with a view to changing oral NSAID use to ibuprofen. It was noted that Leeds had implemented this in August 2015, so that they now discharge patients on ibuprofen 400mg tds.</p>	<p>paediatric use</p> <p>Feedback on switching issues to be obtained from Dr Ming</p> <p>This issue to be raised with the F&W health group, for discussion at their governance meeting and feedback to D&TC.</p>	<p>SPG to liaise with Jane Morgan, Neurology Pharmacist for feedback</p> <p>POB to liaise with the HG lead Pharmacist, for F&W health group to reconsider the issue.</p>	<p>SPG</p> <p>POB</p>	<p>11/16</p> <p>11/16</p>	
2016.10.11	Chairs approvals	<ul style="list-style-type: none"> Zafirlukast – asthma – Prof A Morice 	Noted	No Further Action			10/16
2016.10.12	Issues to escalate to Operational Quality Committee	None					10/16

2016.10.13	Any other Business	None					10/16
2016.10.14	Date and Time of Next Meeting	Date – Thursday 10 th November Time - 8.15am-9.30am Venue – The Board Room, Alderson House, HRI					